Stockreport

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Associ...

Benitec Biopharma Inc.  (BNTC) 
US:NASDAQ Investor Relations: benitec.com/for-investors/investor-faqs
PDF significant improvements in throat closure, throat emptying, and total dysphagic symptom burden - OPMD Patients treated with low dose BB-301 experienced highly durable [Read more]